Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Dysrhythmias V: Evaluating Dysrhythmias01:30

Dysrhythmias V: Evaluating Dysrhythmias

Dysrhythmias, also known as arrhythmias, are disturbances in the heart's rhythm that range from benign to life-threatening. A thorough evaluation is crucial for appropriate management and involves a comprehensive medical history, physical examination, and various diagnostic tests.Medical HistorySymptoms: Collect detailed information on palpitations, dizziness, syncope, chest pain, and fatigue. Note their onset, frequency, and triggers.Previous Cardiac Issues: Document any history of heart...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating metabolomic and lipidomic profiles distinguish patients with acute heart failure de novo vs. worsening of heart failure.

Polish archives of internal medicine·2026
Same author

Worsening renal function in acute heart failure: a hemoconcentration-conditioned interpretation with ranges of benefit, safety, and harm.

Revista espanola de cardiologia (English ed.)·2026
Same author

A Machine-Learning Model for Accurate Diuresis Prediction in Acute Heart Failure (DRC-AHF).

ESC heart failure·2026
Same author

A Contemporary Perspective on Acute Decompensated Heart Failure Classification: A State-of-the-art Review from an International Expert Group.

Cardiac failure review·2026
Same author

Acute Myocardial Infarction versus Acute Decompensated Heart Failure in Cardiogenic Shock: A Systematic Review and Meta-Analysis of Clinical Phenotypes and Mortality.

European journal of heart failure·2026
Same author

Contemporary Management of Acute Heart Failure: From Emergency Presentation to Long-Term Remission.

Journal of the American College of Cardiology·2026

Related Experiment Video

Updated: May 10, 2026

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure
16:19

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure

Published on: September 13, 2014

Liver function tests in patients with acute heart failure.

Jan Biegus1, Robert Zymliński, Mateusz Sokolski

  • 1Centre for Heart Diseases, 4th Military Hospital, Wrocław, Poland. janbiegus@o2.pl

Polskie Archiwum Medycyny Wewnetrznej
|October 6, 2012
PubMed
Summary

Abnormal liver function tests (LFTs) are common in acute heart failure (AHF) patients, affecting prognosis. Elevated bilirubin specifically indicates impaired hemodynamics in AHF.

More Related Videos

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Related Experiment Videos

Last Updated: May 10, 2026

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure
16:19

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure

Published on: September 13, 2014

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Area of Science:

  • Cardiology
  • Hepatology
  • Internal Medicine

Background:

  • Acute heart failure (AHF) is frequently linked to multiorgan dysfunction, potentially worsening patient outcomes.
  • Liver dysfunction is a recognized complication of AHF, but its prevalence and prognostic impact require further elucidation.

Purpose of the Study:

  • To determine the frequency of abnormal liver function tests (LFTs) in patients with AHF.
  • To identify clinical factors associated with abnormal LFTs in AHF.
  • To assess the prognostic significance of abnormal LFTs in AHF.

Main Methods:

  • Retrospective analysis of 189 AHF patients.
  • Assessment of serum bilirubin, AST, ALT, and albumin levels on admission.
  • Definition of abnormal LFTs as values outside the normal range.

Main Results:

  • Abnormal LFTs were prevalent: AST (46%), ALT (31%), bilirubin (33%), albumin (44%).
  • High hemoglobin and NT-proBNP levels were associated with abnormal AST, ALT, and albumin.
  • Elevated bilirubin correlated with higher right atrial pressure and was linked to increased 180-day mortality.
  • Low albumin and markedly elevated AST/ALT also predicted increased mortality.

Conclusions:

  • Abnormal LFTs are frequent in AHF and carry prognostic implications.
  • Elevated bilirubin is a key indicator of hemodynamic compromise in AHF.
  • LFTs, particularly bilirubin, albumin, AST, and ALT, provide valuable prognostic information in AHF.